Cargando…
Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
BACKGROUND: A single‐agent of anti programmed cell death 1/programmed cell death ligand 1 (anti‐PD‐1/PD‐L1) therapy has been explored for resectable lung cancer before surgery. However, the effectiveness and safety of neoadjuvant programmed cell death 1 (PD‐1) blockade combined with chemotherapy hav...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807321/ https://www.ncbi.nlm.nih.gov/pubmed/34913597 http://dx.doi.org/10.1111/1759-7714.14280 |
_version_ | 1784643642529415168 |
---|---|
author | Feng, Yuan Sun, Wei Zhang, Jie Wang, Yang Chen, Jinfeng Liu, Xinying Wang, Liang Li, Shaolei Lv, Chao Lu, Fangliang Zhang, Jianzhi Hong, Yang Xiao, Shanshan Wang, Tao Jiao, Raymond Wang, Ziping Qi, Liping Li, Nan Yang, Yue Lin, Dongmei Fang, Jian |
author_facet | Feng, Yuan Sun, Wei Zhang, Jie Wang, Yang Chen, Jinfeng Liu, Xinying Wang, Liang Li, Shaolei Lv, Chao Lu, Fangliang Zhang, Jianzhi Hong, Yang Xiao, Shanshan Wang, Tao Jiao, Raymond Wang, Ziping Qi, Liping Li, Nan Yang, Yue Lin, Dongmei Fang, Jian |
author_sort | Feng, Yuan |
collection | PubMed |
description | BACKGROUND: A single‐agent of anti programmed cell death 1/programmed cell death ligand 1 (anti‐PD‐1/PD‐L1) therapy has been explored for resectable lung cancer before surgery. However, the effectiveness and safety of neoadjuvant programmed cell death 1 (PD‐1) blockade combined with chemotherapy have not been published. METHODS: Twenty‐one consecutive patients with potentially resectable squamous cell carcinoma of the lung who received neoadjuvant therapy followed by surgery in Beijing Cancer Hospital were included in this study. Eight patients received two cycles of neoadjuvant platinum‐based doublet chemotherapy combined with anti‐programmed cell death 1 (anti‐PD‐1) therapy, while 13 patients received two cycles of neoadjuvant platinum‐based doublet chemotherapy only. Chest computed tomography was repeated before neoadjuvant treatment and surgery. Adverse events were monitored. The major pathological response (MPR) rate was determined after surgery. Selected specimens were sent for immunohistochemical and multiplex immunofluorescence analyses, and T‐cell receptor DNA sequencing. RESULTS: Compared with neoadjuvant chemotherapy alone, the combination of PD‐1 blockade and chemotherapy increased the pathological complete response rate (37.5% vs. 7.69%) and MPR rate (50% vs. 38.46%). The pathological and radiological evaluations are not consistent. No unknown adverse effects were reported for all the patients. More tumor infiltrating lymphocytes were observed in patients who received PD‐1 blockade. No unknown pathological features associated with PD‐1 blockade were found. Immune suppression in the peritumoral spaces around the residual tumor cells was observed. The amino acid sequences of the T‐cell receptors are not significantly shared among the patients. CONCLUSIONS: The combination of neoadjuvant chemotherapy and PD‐1 blockade is safe and feasible, and might indicate an increased MPR and pathological complete response rate. More investigations are needed for the best combination of the neoadjuvant therapy. |
format | Online Article Text |
id | pubmed-8807321 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-88073212022-02-04 Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung Feng, Yuan Sun, Wei Zhang, Jie Wang, Yang Chen, Jinfeng Liu, Xinying Wang, Liang Li, Shaolei Lv, Chao Lu, Fangliang Zhang, Jianzhi Hong, Yang Xiao, Shanshan Wang, Tao Jiao, Raymond Wang, Ziping Qi, Liping Li, Nan Yang, Yue Lin, Dongmei Fang, Jian Thorac Cancer Original Articles BACKGROUND: A single‐agent of anti programmed cell death 1/programmed cell death ligand 1 (anti‐PD‐1/PD‐L1) therapy has been explored for resectable lung cancer before surgery. However, the effectiveness and safety of neoadjuvant programmed cell death 1 (PD‐1) blockade combined with chemotherapy have not been published. METHODS: Twenty‐one consecutive patients with potentially resectable squamous cell carcinoma of the lung who received neoadjuvant therapy followed by surgery in Beijing Cancer Hospital were included in this study. Eight patients received two cycles of neoadjuvant platinum‐based doublet chemotherapy combined with anti‐programmed cell death 1 (anti‐PD‐1) therapy, while 13 patients received two cycles of neoadjuvant platinum‐based doublet chemotherapy only. Chest computed tomography was repeated before neoadjuvant treatment and surgery. Adverse events were monitored. The major pathological response (MPR) rate was determined after surgery. Selected specimens were sent for immunohistochemical and multiplex immunofluorescence analyses, and T‐cell receptor DNA sequencing. RESULTS: Compared with neoadjuvant chemotherapy alone, the combination of PD‐1 blockade and chemotherapy increased the pathological complete response rate (37.5% vs. 7.69%) and MPR rate (50% vs. 38.46%). The pathological and radiological evaluations are not consistent. No unknown adverse effects were reported for all the patients. More tumor infiltrating lymphocytes were observed in patients who received PD‐1 blockade. No unknown pathological features associated with PD‐1 blockade were found. Immune suppression in the peritumoral spaces around the residual tumor cells was observed. The amino acid sequences of the T‐cell receptors are not significantly shared among the patients. CONCLUSIONS: The combination of neoadjuvant chemotherapy and PD‐1 blockade is safe and feasible, and might indicate an increased MPR and pathological complete response rate. More investigations are needed for the best combination of the neoadjuvant therapy. John Wiley & Sons Australia, Ltd 2021-12-15 2022-02 /pmc/articles/PMC8807321/ /pubmed/34913597 http://dx.doi.org/10.1111/1759-7714.14280 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Feng, Yuan Sun, Wei Zhang, Jie Wang, Yang Chen, Jinfeng Liu, Xinying Wang, Liang Li, Shaolei Lv, Chao Lu, Fangliang Zhang, Jianzhi Hong, Yang Xiao, Shanshan Wang, Tao Jiao, Raymond Wang, Ziping Qi, Liping Li, Nan Yang, Yue Lin, Dongmei Fang, Jian Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung |
title | Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung |
title_full | Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung |
title_fullStr | Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung |
title_full_unstemmed | Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung |
title_short | Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung |
title_sort | neoadjuvant pd‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807321/ https://www.ncbi.nlm.nih.gov/pubmed/34913597 http://dx.doi.org/10.1111/1759-7714.14280 |
work_keys_str_mv | AT fengyuan neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT sunwei neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT zhangjie neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT wangyang neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT chenjinfeng neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT liuxinying neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT wangliang neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT lishaolei neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT lvchao neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT lufangliang neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT zhangjianzhi neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT hongyang neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT xiaoshanshan neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT wangtao neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT jiaoraymond neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT wangziping neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT qiliping neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT linan neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT yangyue neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT lindongmei neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung AT fangjian neoadjuvantpd1inhibitorcombineswithchemotherapyversusneoadjuvantchemotherapyinresectablesquamouscellcarcinomaofthelung |